Additional Listing

Ardana PLC
03 May 2006

3 May 2006


                                 BLOCK LISTING


Edinburgh, UK, 03 May 2006;  Ardana plc (LSE:ARA) the emerging pharmaceutical
company focused on improving human reproductive health, today announces that
application has been made to the UK Listing Authority and the London Stock
Exchange for a block listing of 2,494,967 ordinary shares of 1 (one) pence each.
  The application is in respect of shares to be allotted pursuant to the
exercise of options under the Ardana Bioscience Employees' share option scheme,
Ardana Ltd Employees' share option scheme and certain individual option
agreements between Ardana plc and non-executive directors and non-employees.



For more information contact:


Ardana
Maureen Lindsay                           Tel: + 44 (0) 131 226 8550



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $23.8
billion market.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.



Ardana's four lead products are summarised below:



•   StriantTM SR, a testosterone replacement therapy for which Ardana has
    marketing rights in Europe, has already been launched by Ardana through its 
    own sales force in the UK as a treatment for men with confirmed hypogonadism

•   Teverelix LA, in development for three initial indications: prostate cancer 
    and benign prostatic hyperplasia (both indications are at the phase II 
    stage), and endometriosis (currently in phase I)

•   Testo Cream, a transdermal testosterone delivery system in phase II for the 
    treatment of male hypogonadism

•   Invicorp(R), an injectable combination drug treatment for erectile
    dysfunction, already approved in Denmark and for which Ardana has marketing 
    and manufacturing rights in Europe. Launch is expected in H2 2006



In addition, Ardana has a strong portfolio of follow-on products in development.
Ardana completed its IPO on the London Stock Exchange in March 2005 raising
£21 million.

For further information please see www.ardana.co.uk







                      This information is provided by RNS
            The company news service from the London Stock Exchange